Supplementary figures

Prognostic value of blood-based fibrosis biomarkers in patients with metastatic colorectal cancer receiving chemotherapy and bevacizumab

Neel I. Nissen[1,2#*], Stephanie Kehlet[2#], Mogens K. Boisen[3], Maria Liljefors[4], Christina Jensen[2], Astrid Z. Johansen[3], Julia S. Johansen[3,5,6], Janine T. Erler[1], Morten Karsdal[2], Joachim H. Mortensen [2], Anette Høye[1], and Nicholas Willumsen[2]

[#]authors contributed equally to the work

[*]*Corresponding author:* Neel Ingemann Nissen, Herlev Hovedgade 205-207 2730 Herlev, Denmark. +45 4452 5252, nin@nordicbio.com

[1]Biotech Research & Innovation Centre (BRIC), University of Copenhagen (UCPH), Denmark.

[2] Biomarkers & Research, Nordic Bioscience, Herlev, Denmark.

[3] Department of Oncology, Herlev and Gentofte Hospital, Copenhagen University Hospital, Denmark.

[4] Department of Clinical Science, Intervention and Technology, Karolinska University Hospital Huddinge, Stockholm, Sweden

[5] Department of Medicine, Herlev and Gentofte Hospital, Copenhagen University Hospital, Denmark.

[6] Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark

Figure S1: Assessment of the prognostic potential of low and high (median) biomarker levels in patients in first line chemotherapy a) PRO-C3 (formation of collagen type III), b) PRO-C6 (formation of collagen type VI), c) C6M (degradation of collagen type VIα1) and d) C6Mα3 (degradation of collagen type VIα3) serum levels by Kaplan Meier plots. Cox proportional-hazards regression was used to calculate the hazard ratios (HR) with 95% CI and p-values. A $p<0.05$ was considered significant.

Figure S2: Assessment of the prognostic potential of low and high (median) biomarker levels in patients in second or later line of chemotherapy a) PRO-C3 (formation of collagen type III), b) PRO-C6 (formation of collagen type VI), c) C6M (degradation of collagen type VIα1) and d) C6Mα3 (degradation of collagen type VIα3) serum levels by Kaplan Meier plots. Cox proportional-hazards regression was used to calculate the hazard ratios (HR) with 95% CI and p-values. A $p<0.05$ was considered significant.

Fig S1:

a

PRO-C3	Low	High
Events/total	50/66	65/66
Median survival (months)	25.0	13.2
HR (95% CI), high PRO-C3	2.33 (1.60-3.40)	
P-value	<0.0001	

Number at risk
Group: Low PRO-C3
66   52   36   13   8   1   0
Group: High PRO-C3
66   36   12   4   4   1   0

b

PRO-C6	Low	High
Events/total	56/66	59/66
Median survival (months)	21.4	13.6
HR (95% CI), high PRO-C6	1.33 (0.92-1.92)	
P-value	0.1249	

Number at risk
Group: Low PRO-C6
66   51   28   9   6   1   0
Group: High PRO-C6
66   37   20   8   6   1   0

c

C6M	Low	High
Events/total	55/66	60/66
Median survival (months)	22.3	14.1
HR (95% CI), high C6M	1.48 (1.02-2.13)	
P-value	0.0380	

Number at risk
Group: Low C6M
66   49   31   10   8   1   0
Group: High C6M
66   39   17   7   4   1   0

d

C6Mα3	Low	High
Events/total	54/66	57/66
Median survival (months)	24.2	13.2
HR (95% CI), high C6Mα3	1.72 (1.18-2.51)	
P-value	0.0048	

Number at risk
Group: Low C6Ma3
65   50   32   12   8   2   0
Group: High C6Ma3
63   34   14   5   4   0   0

Fig S2:

a

PRO-C3	Low	High
Events/total	59/60	55/60
Median survival (months)	20.7	12.1
HR (95% CI), high PRO-C3	2.06 (1.38-3.09)	
P-value	<0.0001	

Number at risk
Group: Low PRO-C3

| 60 | 41 | 26 | 12 | 5 | 4 | 1 | 0 |

Group: High PRO-C3

| 60 | 31 | 10 | 3 | 0 | 0 | 0 | 0 |

b

PRO-C6	Low	High
Events/total	49/60	55/60
Median survival (months)	19.1	11.4
HR (95% CI), high PRO-C6	2.04 (1.37-3.05)	
P-value	0.0005	

Number at risk
Group: Low PRO-C6

| 60 | 42 | 25 | 13 | 4 | 3 | 1 | 0 |

Group: High PRO-C6

| 60 | 30 | 11 | 2 | 1 | 1 | 0 | 0 |

c

C6M	Low	High
Events/total	49/60	55/60
Median survival (months)	17.1	12.0
HR (95% CI), high C6M	1.44 (1.00-2.12)	
P-value	0.0660	

Number at risk
Group: Low C6M

| 60 | 42 | 21 | 10 | 2 | 1 | 0 | 0 |

Group: High C6M

| 60 | 30 | 15 | 5 | 3 | 3 | 1 | 0 |

d

C6Mα3	Low	High
Events/total	35/42	38/42
Median survival (months)	17.4	14.4
HR (95% CI), high C6Mα3	1.25 (0.79-2.00)	
P-value	0.3481	

Number at risk
Group: Low C6Ma3

| 42 | 30 | 14 | 7 | 2 | 2 | 0 | 0 |

Group: High C6Ma3

| 42 | 23 | 13 | 5 | 2 | 2 | 1 | 0 |